Lanzhou University Second Hospital
兰州大学第二医院
Listed for 19 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
Official links opened and checked on 2026-11-08.
Research at Lanzhou University Second Hospital
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Oesophageal squamous cell carcinoma食管鳞状细胞癌10 papers led
- Hepatocellular carcinoma肝细胞癌45 papers led
- Stomach cancer胃癌108 papers led
- Chordoma脊索瘤1 paper led
- Osteosarcoma骨肉瘤15 papers led
- Gastrointestinal stromal tumour胃肠道间质瘤5 papers led
- Neuroblastoma神经母细胞瘤2 papers led
- Ewing sarcoma尤文肉瘤2 papers led
- Multiple myeloma多发性骨髓瘤12 papers led
- IgG4-related diseaseIgG4相关性疾病2 papers led
- Myasthenia gravis重症肌无力2 papers led
- Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎2 papers led
- Takayasu arteritis大动脉炎0 papers led
- Idiopathic pulmonary fibrosis特发性肺纤维化0 papers led
- Duchenne muscular dystrophy杜氏肌营养不良1 paper led
- IgA nephropathyIgA 肾病2 papers led
- Gaucher disease戈谢病0 papers led
- Primary biliary cholangitis原发性胆汁性胆管炎0 papers led
- Primary sclerosing cholangitis原发性硬化性胆管炎1 paper led
Not listed for: Nasopharyngeal carcinoma, Hepatoblastoma, Retinoblastoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, Moyamoya disease, Wilson disease, Biliary atresia, Hepatic echinococcosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Behçet disease, Alport syndrome, Niemann–Pick disease type C, Osteogenesis imperfecta, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Oesophageal squamous cell carcinoma
食管鳞状细胞癌Led 10 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Lanzhou for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma
No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led10
- Predictive value of 18F-FDG PET/CT-based radiomics model for lymph node metastasis in esophageal squamous cell carcinoma.
- BRD4 Induces Esophageal Squamous Cell Carcinoma Progression via the Wnt/β-catenin Pathway.
- Neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell carcinoma: a retrospective study with 2-year survival analysis.
- PYCR1 Promotes Esophageal Squamous Cell Carcinoma by Interacting With EGFR to Affecting the PI3K/Akt/mTOR Signaling Pathway.
- Downregulation of ALDH5A1 suppresses cisplatin resistance in esophageal squamous cell carcinoma by regulating ferroptosis signaling pathways.
- Utility of near-infrared fluorescence imaging with indocyanine green in resection of oesophageal squamous cell carcinoma: A literature review and a case report.
- Molecular mechanism underlying epithelial-mesenchymal transformation and cisplatin resistance in esophageal squamous cell carcinoma.
- Epithelial-Mesenchymal Transition Gene Signature Is Associated with Neoadjuvant Chemoradiotherapy Resistance and Prognosis of Esophageal Squamous Cell Carcinoma.
- Long non‑coding RNA PART1: dual role in cancer.
- SYNGR2 serves as a prognostic biomarker and correlates with immune infiltrates in esophageal squamous cell carcinoma.
All its trials on ClinicalTrials.gov, any status2
- A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
- Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Cancer
Hepatocellular carcinoma
肝细胞癌Led 45 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
2 hospitals in Lanzhou for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingAnlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
- Phase
- Phase 3
- Started
- 2023-05
- Registry
- NCT05862337
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Lanzhou, Luzhou, Nanchang, Nanchong, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Taizhou, Tianjin, Urumqi, Wenzhou, Xi'an, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led45
- Whole-lesion iodine map histogram analysis combined with focal ROI iodine concentrations for preoperative prediction of cytokeratin 19-positive hepatocellular carcinoma.
- Deep learning 3D super-resolution radiomics model based on Gd-enhanced MRI for improving preoperative prediction of HCC pathological grading.
- Prediction of Posthepatectomy Liver Failure in Narrow Resection Margins HCC: A Model Based on Iodine Map Histogram Analysis of Nontumorous Liver Parenchyma.
- Comprehensive molecular characteristics of hepatocellular carcinoma based on multi-omics analysis.
- Visit‑to‑visit variability of inflammation-immunity indices and prognosis in hepatocellular carcinoma.
- Adherence to STARD guidelines in miRNA diagnostic accuracy studies for hepatocellular carcinoma: a systematic review.
- Study on the concordance in the diagnostic efficacy between CEUS LI-RADS and CT/MR LI-RADS for HCC.
- Breaking bottlenecks: the future of hepatocellular carcinoma clinical trials and therapeutic targets.
- APM-Related gene signature model to predict prognosis and immunotherapy response in hepatocellular carcinoma.
- Therapeutic targets for hepatocellular carcinoma identified using proteomics and Mendelian randomization.
- A spreadable self-gelling hemostatic powder sensitizes CAR-NK cell therapy to prevent hepatocellular carcinoma recurrence postresection.
- Post-translational modifications in hepatocellular carcinoma: mechanisms and therapeutic potential.
- Causal relationship between serum bilirubin, cholelithiasis and hepatobiliary and pancreatic malignancy: A bidirectional and 2-sample Mendelian randomization study.
- A contrast‑enhanced CT histogram‑driven nomogram for predicting post‑radiotherapy liver regeneration in hepatocellular carcinoma.
- Integrating single-cell RNA sequencing, WGCNA, and machine learning to identify key biomarkers in hepatocellular carcinoma.
- Progress of Pyruvate Kinase M2 in Hepatocellular Carcinoma-Associated Signaling Pathway.
- P2RX4 promotes hepatocellular carcinoma progression via calcium-mediated PI3K/AKT activation and immune remodeling.
- Alpha-fetoprotein upregulates hepatocellular carcinoma cell-intrinsic PD-1 expression through the LATS2/YAP/TEAD1 pathway.
- The Role of Pyruvate Kinase M2 Posttranslational Modification in the Occurrence and Development of Hepatocellular Carcinoma.
- FXa-mediated PAR-2 promotes the efficacy of immunotherapy for hepatocellular carcinoma through immune escape and anoikis resistance by inducing PD-L1 transcription.
- Prognostic Significance of Iron Metabolism and Immune-Related Genes as Risk Markers in Hepatocellular Carcinoma.
- Integrative analysis of multi-omics data identified PLG as key gene related to Anoikis resistance and immune phenotypes in hepatocellular carcinoma.
- Transarterial Chemoembolization Combined with Lenvatinib for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
- Identification and verification of a prognostic autophagy-related gene signature in hepatocellular carcinoma.
- Different power modes of microwave ablation for hepatocellular carcinoma: Evaluation of recurrence rate and factors related to recurrence.
- Development and validation of a coagulation-related genes prognostic model for hepatocellular carcinoma.
- MicroRNA-5195-3p mediated malignant biological behaviour of insulin-resistant liver cancer cells via SOX9 and TPM4.
- Predicting glypican-3 expression in hepatocellular carcinoma: A comprehensive analysis using combined contrast-enhanced ultrasound and clinical factors.
- Neutrophil extracellular traps regulating tumorimmunity in hepatocellular carcinoma.
- Establishment and characterization of a new Chinese hepatocellular carcinoma cell line, Hep-X1.
- PA-MSHA Regulates PD-L1 Expression in Hepatoma Cells.
- Predictive Roles of ADAM17 in Patient Survival and Immune Cell Infiltration in Hepatocellular Carcinoma.
- RPS24 Is Associated with a Poor Prognosis and Immune Infiltration in Hepatocellular Carcinoma.
- Contrast-enhanced ultrasound demonstrates greater adjuvant potential: past, current status, and future applications in Hepatocellular carcinoma early diagnosis.
- BUB1 predicts poor prognosis and immune status in liver hepatocellular carcinoma.
- Study on correlation between two-dimensional ultrasound, contrast-enhanced ultrasound and microvascular invasion in hepatocellular carcinoma.
- Overexpression of Ribosomal Protein S6 Kinase A4 (RPS6KA4) Predicts a Poor Prognosis in Hepatocellular Carcinoma Patients: A Study Based on TCGA Samples.
- Relationship between Intestinal Microflora and Hepatocellular Cancer Based on Gut-Liver Axis Theory.
- The effect of metformin usage on survival outcomes for hepatocellular carcinoma patients with type 2 diabetes mellitus after curative therapy.
- Anticancer Effect of Arbutin on Diethylnitrosamine-Induced Liver Carcinoma in Rats via the GRP and GADD Pathway.
- Overexpressed PAQR4 predicts poor overall survival and construction of a prognostic nomogram based on PAQR family for hepatocellular carcinoma.
- Bioinformatic Evidence Reveals that Cell Cycle Correlated Genes Drive the Communication between Tumor Cells and the Tumor Microenvironment and Impact the Outcomes of Hepatocellular Carcinoma.
- The lncRNA VPS9D1-AS1 Promotes Hepatocellular Carcinoma Cell Cycle Progression by Regulating the HuR/CDK4 Axis.
- The expression and clinical significance of TPM4 in hepatocellular carcinoma.
- Transcript levels of spindle and kinetochore-associated complex 1/3 as prognostic biomarkers correlated with immune infiltrates in hepatocellular carcinoma.
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status2
- Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
- A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
Cancer
Stomach cancer
胃癌Led 108 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 1.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
3 hospitals in Lanzhou for stomach cancer218 hospitals in China for stomach cancer
Open trials with this hospital 4
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingStudy of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
- Phase
- Phase 3
- Started
- 2025-02
- Registry
- NCT06731478
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changzhou, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Linyi, Shanghai, Shenyang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yinchuan, Zhengzhou
- RecruitingNeoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
- Phase
- Phase 3
- Started
- 2025-04
- Registry
- NCT06925243
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesGuangzhou, Lanzhou
- RecruitingNeoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
- Phase
- Phase 3
- Started
- 2025-05
- Registry
- NCT06949033
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesGuangzhou, Lanzhou
- RecruitingFeasibility of Enhanced Recovery After Surgery Without Prophylactic Abdominal Drainage Tubes After Laparoscopic Distal Gastrectomy For Gastric Cancer
- Phase
- Phase 3
- Started
- 2025-06
- Registry
- NCT07029269
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesFuzhou, Guangzhou, Hangzhou, Lanzhou, Xi'an
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led108
- The snoRNA SNORA21 promotes gastric tumorigenesis by attenuating P53 activity through CHK1 phosphorylation inhibition and PERP-dependent feedback loops.
- TMEM176A drives anti-apoptotic signaling through TGM2-mediated ERK activation in gastric cancer.
- The Value of Double Contrast-Enhanced Ultrasonography in the Differential Diagnosis of Gastric Submucosal Tumors and the Assessment of the Malignant Risk of Gastrointestinal Stromal Tumors.
- Targeted Dual-Responsive Liposomes Co-Deliver Jolkinolide B and Ce6 to Synergistically Enhance the Photodynamic/Immunotherapy Efficacy in Gastric Cancer through the PANoptosis Pathway.
- Identification and prioritization of high-frequency biomarkers and therapeutic targets in gastric cancer trials.
- KLC3 drives gastric cancer progression by stabilizing SLC2A5 to activate MAPK signaling and promote epithelial-mesenchymal transition.
- Identification of multiomics and immune infiltration-associated biomarkers for early gastric cancer: a machine learning-based diagnostic model development study.
- Indocyanine Green-Labeled Antibody-NOTCH2 as a New Fluorescent Molecular Imaging Probe for Gastric Cancer.
- Comparing Quality of Life for Billroth II With Braun Versus Uncut Roux-en-Y Reconstruction After Total Laparoscopic Distal Gastrectomy for Gastric Cancer: A Randomized Clinical Trial.
- The Black Hole of Immune Checkpoint Blocking Therapy for Gastric Cancer: Hyperprogressive Disease.
- ULBP2 CAR-T cells enhance gastric cancer immunotherapy by inhibiting CAF activation.
- Identification and Validation of a Novel Prognostic Signature of Gastric Cancer Based on Seven Complement System-Related Genes: An Integrated Analysis.
- Integrative Analysis Reveals Differential Characteristics of DDR1 Mutant and Wild-type Gastric Cancers and Constructs their Prediction Models.
- Evolving Landscape of HER2-Targeted Therapies for Gastric Cancer Patients.
- Association between different patterns of obesity and the short-term outcomes of gastric cancer surgery.
- Nutritional status of early oral feeding for gastric cancer patients after laparoscopic total gastrectomy: A retrospective cohort study.
- Sequential HIPEC, Claudin18.2-targeted therapy, and CapeOx chemotherapy leading to resolution of peritoneal metastases and curative resection in gastric cancer: a case report and literature review.
- Deep learning and multi-omics reveal programmed cell death-associated diagnostic signatures and prognostic biomarkers in gastric cancer.
- Renal capsule patient-derived xenograft model for gastric cancer: establishment and MRI characterization.
- Targeting the BAG2/CHIP axis promotes gastric cancer apoptosis by blocking apoptosome assembly.
- HER2-positive gastric cancer: from targeted therapy to CAR-T cell therapy.
- Targeting Eg5 using Arry520 combats gastric cancer by inducing monopolar spindles.
- Multi-omic analysis reveals the role of coagulation factor family genes and their predictive value for immune checkpoint inhibitors efficacy in gastric cancer.
- Does ambient particulate matter 1 increase the risk of gastric cancer in the northwest of China?
- Clinical application value of modified overlap anastomosis for Siewert type II and III adenocarcinoma of esophagogastric junction.
- Gastric cancer-derived exosomal let-7 g-5p mediated by SERPINE1 promotes macrophage M2 polarization and gastric cancer progression.
- Targeted DDR1 Treatment Strategy Enhances PD-1 Immunotherapy Efficacy against Gastric Cancer.
- Single-cell RNA sequencing and spatial transcriptomics reveal the heterogeneity and intercellular communication of cancer-associated fibroblasts in gastric cancer.
- Neoadjuvant cadonilimab plus FLOT chemotherapy in locally advanced gastric/gastroesophageal junction adenocarcinoma: A multicenter, phase 2 study.
- Effect of PRKD3 on cell cycle in gastric cancer progression and downstream regulatory networks.
- Nanomaterials in gastric cancer: pioneering precision medicine for diagnosis, therapy, and prevention.
- ELK1 modulates SF3B3 transcriptional activity to stimulate proliferation and inhibit apoptosis in gastric cancer through the activation of the MAPK pathway.
- The impact of GST genetic polymorphisms on the response to oxaliplatin-based chemotherapy and survival prognosis in gastric cancer patients.
- The expression of transmembrane channel-like 5 in gastric cancer and its impact on tumor progression.
- SERPINE1 Facilitates Metastasis in Gastric Cancer Through Anoikis Resistance and Tumor Microenvironment Remodeling.
- A prospective and comparative study on improving the diagnostic accuracy of early gastric cancer based on deep convolutional neural network real-time diagnosis system (with video).
- The role of TMEM119 in gastric adenocarcinoma and its specific effects on immunity.
- A case of neonatal gastric teratoma complicated with occult gastrointestinal hemorrhage misdiagnosed as lymphangioma.
- The current landscape and advances in functional-preserving gastric cancer surgery.
- Historical evolution and current research status of lymph node staging in gastric cancer: a review.
- eIF6: a promising therapeutic target for gastric carcinoma via PI3K/AKT pathway modulation.
- Combination of clinical and spectral-CT iodine concentration for predicting liver metastasis in gastric cancer: a preliminary study.
- Correlation of CT parameters and PD-L1 expression status in gastric cancer.
- Not all carotenoids can reduce the risk of gastric cancer: a systematic review with meta-analysis.
- Exploring the therapeutic potential of diterpenes in gastric cancer: Mechanisms, efficacy, and clinical prospects.
- Prediction of Ki-67 expression in gastric gastrointestinal stromal tumors using histogram analysis of monochromatic and iodine images derived from spectral CT.
- Targeting NUF2 suppresses gastric cancer progression through G2/M phase arrest and apoptosis induction.
- Current status of neoadjuvant immunotherapy for the treatment of gastric cancer.
- The application of organoids in cancers associated with pathogenic infections.
- Whether the use of intravenous contrast-enhanced ultrasound can improve the accuracy of T stage diagnosis of gastric cancer?
- Value of spectral CT parameters in predicting the efficacy of neoadjuvant chemotherapy for gastric cancer.
- Prognostic Value and Therapeutic Significance of CCL Chemokines in Gastric Cancer.
- Mesenchymal Stem Cells Target Gastric Cancer and Deliver Epirubicin via Tunneling Nanotubes for Enhanced Chemotherapy.
- IL-17A in gastric carcinogenesis: good or bad?
- SOX combined with apatinib and camrelizumab in the treatment of resectable locally advanced gastric cancer: a case report.
- UBE2L3 expression in human gastric cancer and its clinical significance.
- High expression of NOTCH2 in gastric adenocarcinoma: A novel early diagnostic target.
- Biological Clock Genes are Crucial and Promising Biomarkers for the Therapeutic Targets and Prognostic Assessment in Gastric Cancer.
- MicroRNAs in Helicobacter pylori-infected gastric cancer: Function and clinical application.
- Photodynamic therapy may salvage chemotherapy failure in gastric cancer: A case report and a literature review.
- EGCG targeting STAT3 transcriptionally represses PLXNC1 to inhibit M2 polarization mediated by gastric cancer cell-derived exosomal miR-92b-5p.
- Imaging advances in efficacy assessment of gastric cancer neoadjuvant chemotherapy.
- Risk of venous thromboembolism in patients undergoing gastric cancer surgery: a systematic review and meta-analysis.
- Glycosyltransferase GLT8D1 and GLT8D2 serve as potential prognostic biomarkers correlated with Tumor Immunity in Gastric Cancer.
- Organoids: Construction and Application in Gastric Cancer.
- PICH Activates Cyclin A1 Transcription to Drive S-Phase Progression and Chemoresistance in Gastric Cancer.
- A novel adenosine signalling-based prognostic signature in gastric cancer and its association with cancer immune features and immunotherapy response.
- A nine-gene signature as prognostic biomarker in gastric cancer by bioinformatics analysis.
- Combined Inhibition of KIF11 and KIF15 as an Effective Therapeutic Strategy for Gastric Cancer.
- Focusing on Helicobacter pylori infection in the elderly.
- Photodynamic therapy improves the outcome of immune checkpoint inhibitors via remodelling anti-tumour immunity in patients with gastric cancer.
- Epidemiology, risk areas and macro determinants of gastric cancer: a study based on geospatial analysis.
- Exploration of gastric carcinogenesis from the relationship between bile acids and intestinal metaplasia and intragastric microorganisms (H. pylori and non-H. pylori).
- A practical recurrence risk model based on Lasso-Cox regression for gastric cancer.
- STAT1 suppresses the transcriptional activity of TRIM21 in gastric cancer.
- Predictive value of 18F-FDG PET/CT multi-metabolic parameters and tumor metabolic heterogeneity in the prognosis of gastric cancer.
- The prognostic value of FAR and a novel FAR-CA125 score in resectable gastric signet ring cell carcinoma patients.
- Exploring the role of PMEPA1 in gastric cancer.
- Exploring the role of FBXO5 in gastric cancer.
- High expression of TMEM200A is associated with a poor prognosis and immune infiltration in gastric cancer.
- Research progress of potential factors influencing photodynamic therapy for gastrointestinal cancer.
- MKRN2 inhibits the proliferation of gastric cancer by downregulating PKM2.
- Identification of differentially expressed miRNAs derived from serum exosomes associated with gastric cancer by microarray analysis.
- Combination of clinical and spectral-CT parameters for predicting lymphovascular and perineural invasion in gastric cancer.
- Meta-Analysis of Efficacy and Safety of Karelizumab Combined with Apatinib in the Treatment of Advanced Gastric Cancer.
- The N6-methyladenosine:mechanisms, diagnostic value, immunotherapy prospec-ts and challenges in gastric cancer.
- MCEMP1 is a potential therapeutic biomarker associated with immune infiltration in advanced gastric cancer microenvironment.
- TCF7L2 promotes anoikis resistance and metastasis of gastric cancer by transcriptionally activating PLAUR.
- Measurement of soluble PD-1 and soluble PD-L1 as well as PD-L1 and PD-1 from perioperative patients with gastric carcinoma.
- Long non-coding RNA TNK2 AS1/microRNA-125a-5p axis promotes tumor growth and modulated phosphatidylinositol 3 kinase/AKT pathway.
- NCAPH regulates gastric cancer progression through DNA damage response.
- Photodynamic Therapy in Combination with Chemotherapy, Targeted, and Immunotherapy As a Successful Therapeutic Approach for Advanced Gastric Adenocarcinoma: A Case Report and Literature Review.
- Therapeutic strategies targeting uPAR potentiate anti-PD-1 efficacy in diffuse-type gastric cancer.
- Clinico-radiological nomogram for preoperatively predicting post-resection hepatic metastasis in patients with gastric adenocarcinoma.
- Single-cell landscape reveals active cell subtypes and their interaction in the tumor microenvironment of gastric cancer.
- Study on the expression of c-Met in gastric cancer and its correlation with preoperative serum tumor markers and prognosis.
- Immune Cell Landscape in Gastric Cancer.
- Long intergenic noncoding RNA00265 promotes proliferation of gastric cancer via the microRNA-144-3p/Chromobox 4 axis.
- Prognostic Value of lncRNA PVT1 for Patients with Gastric Cancer: A Meta-Analysis.
- Construction and Validation of a Novel Prognostic Signature for Intestinal Type of Gastric Cancer.
- Auditory and Visual Stimulation for Abdominal Postoperative Patients Experiencing Enhanced Recovery After Surgery (ERAS).
- Prognostic Value of Combination of Inflammatory and Tumor Markers in Resectable Gastric Cancer.
- Damage Control Surgery Saves Patient with Gastric Lymphoma from Radical Gastrectomy.
- Carcinosarcoma and sarcomatoid carcinoma of the stomach: Two case reports.
- Hyperactivation of HER2-SHCBP1-PLK1 axis promotes tumor cell mitosis and impairs trastuzumab sensitivity to gastric cancer.
- A novel UBE2T inhibitor suppresses Wnt/β-catenin signaling hyperactivation and gastric cancer progression by blocking RACK1 ubiquitination.
- Construction of PD1/CD28 chimeric-switch receptor enhances anti-tumor ability of c-Met CAR-T in gastric cancer.
- Evidence Mapping of Proton Therapy, Heavy Ion Therapy, and Helical Tomotherapy for Gastric Cancer.
Chinese-language papers (not in the count)3
- Research progress in effects of MAGE-A family on gastric cancer.
- [Correlations of 18F-FDG PET/CT Metabolic Parameters and Metabolic Heterogeneity with Human Epidermal Growth Factor Receptor 2 Expression in Patients with Gastric Cancer].
- [Spectral CT multi-parameter imaging in preoperatively evaluation the status of lymphovascular and perineural invasion of gastric cancer].
All its trials on ClinicalTrials.gov, any status14
- Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
- Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
- Feasibility of Enhanced Recovery After Surgery Without Prophylactic Abdominal Drainage Tubes After Laparoscopic Distal Gastrectomy For Gastric Cancer
- Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
- A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China
- Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
- Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
- PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer
- A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression
- A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Gastric Carcinoma
- Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901
- Comparing the Prognosis of Patients With Cardia and Non-cardia Gastric Cancer.
- Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer
- Dendritic Cell-based Immunotherapy in Treatment Gastric Cancer
Cancer
Chordoma
脊索瘤Led 1 of the 105 English-language PubMed papers on chordoma with an author in mainland China, 2021–2025: 0.9%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Lanzhou for chordoma88 hospitals in China for chordoma
No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Cancer
Osteosarcoma
骨肉瘤Led 15 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.7%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
8 hospitals in Lanzhou for osteosarcoma742 hospitals in China for osteosarcoma
No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led15
- Long non-coding RNA BCAR4 regulates osteosarcoma progression by targeting microRNA-1260a.
- Thermo-responsive nano-hydrogel-based delivery of Saikosaponin a to enhance anti-PD-1 therapy in osteosarcoma.
- PDK1, associated with glycolytic metabolism, is a potential prognostic biomarker in osteosarcoma.
- The Role of Ubiquitination in Osteosarcoma Development and Therapies.
- Ferroptosis defense mechanisms: The future and hope for treating osteosarcoma.
- Circ_0004674 regulation of glycolysis and proliferation mechanism of osteosarcoma through miR-140-3p/TCF4 pathway.
- Silencing circular RNA hsa_circABCC1 inhibits osteosarcoma progression through down-regulating HDAC4 via sponging miR-591.
- Research Progress of Nanomaterials in Chemotherapy of Osteosarcoma.
- The value of Ki-67 as a prognostic biomarker in osteosarcoma: A systematic review and meta-analysis.
- Extraosseous Ewing's sarcoma/peripheral primitive neuroectodermal tumour of the kidney: a case report and literature review.
- Roles of MET in human cancer.
- KMT5A Knockdown Suppresses Osteosarcoma Cell Proliferation and Metastasis Through Ꞵ-Catenin Signalling.
- TRIP13 knockdown inhibits the proliferation, migration, invasion, and promotes apoptosis by suppressing PI3K/AKT signaling pathway in U2OS cells.
- Comparative analysis of magnetic resonance imaging and pathological findings of microcystic meningioma and meningeal Ewing sarcoma/peripheral primitive neuroectodermal tumors.
- Exosomal miR-21-5p derived from bone marrow mesenchymal stem cells promote osteosarcoma cell proliferation and invasion by targeting PIK3R1.
Earlier papers (2016–2020)9
- Sphingosine kinase 1 contributes to doxorubicin resistance and glycolysis in osteosarcoma.
- Silencing of RIPK4 inhibits epithelial‑mesenchymal transition by inactivating the Wnt/β‑catenin signaling pathway in osteosarcoma.
- Rosmarinic acid exerts an anticancer effect on osteosarcoma cells by inhibiting DJ-1 via regulation of the PTEN-PI3K-Akt signaling pathway.
- HOXA5 overexpression promotes osteosarcoma cell apoptosis through the p53 and p38α MAPK pathway.
- COX‑2 promotes epithelial‑mesenchymal transition and migration in osteosarcoma MG‑63 cells via PI3K/AKT/NF‑κB signaling.
- WNT5A promotes migration and invasion of human osteosarcoma cells via SRC/ERK/MMP-14 pathway.
- Pelargonidin induces antitumor effects in human osteosarcoma cells via autophagy induction, loss of mitochondrial membrane potential, G2/M cell cycle arrest and downregulation of PI3K/AKT signalling pathway.
- Exosomes Derived from Human Bone Marrow Mesenchymal Stem Cells Promote Tumor Growth Through Hedgehog Signaling Pathway.
- Long Noncoding RNA GAS5 Suppresses Cell Growth and Epithelial-Mesenchymal Transition in Osteosarcoma by Regulating the miR-221/ARHI Pathway.
Cancer
Gastrointestinal stromal tumour
胃肠道间质瘤Led 5 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 1.0%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Lanzhou for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour
No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led5
- The Value of Double Contrast-Enhanced Ultrasonography in the Differential Diagnosis of Gastric Submucosal Tumors and the Assessment of the Malignant Risk of Gastrointestinal Stromal Tumors.
- A Prostatic Extra-Gastrointestinal Stromal Tumor Treated by Surgery: A Case Report with 7-Year Follow-Up and Review of Literature.
- Whole-lesion iodine map histogram analysis in the risk classification of gastrointestinal stromal tumors: comparison with single-slice iodine concentration measurements.
- Prediction of Ki-67 expression in gastric gastrointestinal stromal tumors using histogram analysis of monochromatic and iodine images derived from spectral CT.
- Giant gastrointestinal stromal tumor of the jejunum with spontaneous rupture and hemorrhage: A case report.
Earlier papers (2016–2020)1
Cancer
Neuroblastoma
神经母细胞瘤Led 2 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Lanzhou for neuroblastoma352 hospitals in China for neuroblastoma
No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
Cancer
Ewing sarcoma
尤文肉瘤Led 2 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 1.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Lanzhou for Ewing sarcoma139 hospitals in China for Ewing sarcoma
No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
Blood disorders
Multiple myeloma
多发性骨髓瘤Led 12 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.7%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
3 hospitals in Lanzhou for multiple myeloma178 hospitals in China for multiple myeloma
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- Not yet recruitingClinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
- Phase
- Phase 3
- Started
- 2026-06
- Registry
- NCT07569757
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengde, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Xi'an, Xuzhou, Zhanjiang, Zhengzhou, Zhuzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led12
- Analysis of discordant results in multi-technique platform-based MRD detection in multiple myeloma and the clinical decision-making dilemma.
- Magnetic resonance imaging-based nomograms predict high-risk cytogenetic abnormalities in multiple myeloma: a two-centre study.
- Efficacy and Safety of triplet versus doublet regimens in patients with multiple myeloma: A systematic review and meta-analysis.
- Threonine and tyrosine kinase promotes multiple myeloma progression by regulating regucalcin expression.
- Peroxiredoxins as novel indicators in multiple myeloma associated with ferroptosis and immune infiltration.
- Construction of the prediction model for multiple myeloma based on machine learning.
- Elevated programmed cell death-1 protein/ligand (PD-1/PD-L1) and variants are associated with susceptibility to multiple myeloma: a case-control study in the Chinese cohort.
- LGR4 promotes tumorigenesis by activating TGF-β1/Smad signaling pathway in multiple myeloma.
- Obesity as a risk factor for multiple myeloma: insight on the role of adipokines.
- The yin-yang effects of immunity: From monoclonal gammopathy of undetermined significance to multiple myeloma.
- Nontargeted and targeted metabolomics approaches reveal the key amino acid alterations involved in multiple myeloma.
- Efficacy and safety of daratumumab in the treatment of multiple myeloma: a systematic review and meta-analysis.
Chinese-language papers (not in the count)6
- [Prognosis and immune biomarkers of multiple myeloma].
- [Prognostic Value of A New Risk Stratification Model (R2-ISS) in Newly Diagnosed Multiple Myeloma].
- [A Prognostic Nomogram Based on Response to Bortezomib and BTK Expression for Treatment-Experienced Multiple Myeloma Patients].
- [Clinical Significance of sFLC/MP Level and Light Chain Escape in Patients with Multiple Myeloma Relapse].
- [The Influence of CONUT Score on the Prognosis of Patients with Multiple Myeloma].
- [Multiple myeloma with multiple extramedullary lesions of pancreas, stomach and skin: a case report].
Other diseases
IgG4-related disease
IgG4相关性疾病Led 2 of the 246 English-language PubMed papers on IgG4-related disease with an author in mainland China, 2021–2025: 0.8%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Lanzhou for IgG4-related disease46 hospitals in China for IgG4-related disease
No open trial on IgG4-related disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led2
More papers found outside PubMed (not counted)1
Other diseases
Myasthenia gravis
重症肌无力Led 2 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Lanzhou for myasthenia gravis93 hospitals in China for myasthenia gravis
No open trial on myasthenia gravis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led2
All its trials on ClinicalTrials.gov, any status1
Other diseases
Anti-NMDA receptor encephalitis
抗 NMDA 受体脑炎Led 2 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 0.8%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Lanzhou for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis
No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
Earlier papers (2016–2020)1
Other diseases
Takayasu arteritis
大动脉炎Led no English-language PubMed papers on Takayasu arteritis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Lanzhou for Takayasu arteritis108 hospitals in China for Takayasu arteritis
No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Chinese-language papers (not in the count)1
Other diseases
Idiopathic pulmonary fibrosis
特发性肺纤维化Led no English-language PubMed papers on idiopathic pulmonary fibrosis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Lanzhou for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis
No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Other diseases
Duchenne muscular dystrophy
杜氏肌营养不良Led 1 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Lanzhou for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy
No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
Other diseases
IgA nephropathy
IgA 肾病Led 2 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Lanzhou for IgA nephropathy346 hospitals in China for IgA nephropathy
No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
All its trials on ClinicalTrials.gov, any status2
Other diseases
Gaucher disease
戈谢病Led no English-language PubMed papers on Gaucher disease in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Lanzhou for Gaucher disease41 hospitals in China for Gaucher disease
No open trial on Gaucher disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
Other diseases
Primary biliary cholangitis
原发性胆汁性胆管炎Led no English-language PubMed papers on primary biliary cholangitis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
1 hospital in Lanzhou for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingFenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis
- Phase
- Phase 3
- Started
- 2023-02
- Registry
- NCT05751967
Age 18 years to 75 years (registered criteria)
Led by Xijing Hospital; 6 listed hospitals as study sitesChengdu, Guangzhou, Lanzhou, Nanjing, Shenyang, Tianjin, Xi'an
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status2
Other diseases
Primary sclerosing cholangitis
原发性硬化性胆管炎Led 1 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 1.0%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Lanzhou for primary sclerosing cholangitis90 hospitals in China for primary sclerosing cholangitis
No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
Getting in touch
Name card to show staff or a driver
兰州大学第二医院
Lanzhou University Second Hospital
兰州
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
ROR
Second Hospital of Lanzhou University; Lanzhou University Second hospital; Xigu Branch of the Second Hospital of Lanzhou University; Lanzhou University Second Clinical Medical College